FLT3 is an inclusion eligibility criterion in 1 clinical trial for blastic plasmacytoid dendritic cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and blastic plasmacytoid dendritic cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

MECOM is an inclusion eligibility criterion in 2 clinical trials for blastic plasmacytoid dendritic cell neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and blastic plasmacytoid dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 2 clinical trials for blastic plasmacytoid dendritic cell neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MLF1 status and blastic plasmacytoid dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 2 clinical trials for blastic plasmacytoid dendritic cell neoplasm, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and blastic plasmacytoid dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 2 clinical trials for blastic plasmacytoid dendritic cell neoplasm, of which 2 are open and 0 are closed. Of the trials that contain RPN1 status and blastic plasmacytoid dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].